The Cooperative Study Group for Autoimmune Disease Prevention (CSGADP) was established in 2001 as a collaborative network of investigators with a focus on prevention of autoimmune disease, defined as halting the development of autoimmune disease prior to clinical onset by means other than global immunosuppression, and an emphasis on Type 1 diabetes. The initial network of five cooperative agreements was funded by NIAID, the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), the National Institutes of Health (NIH) Office for Research in Women’s Health, and the Juvenile Diabetes Research Foundation International. Following the first five-year funding period, the Study Group was renewed through RFA AI05-026 with the award of six five-year cooperative agreements.
The mission of CSGADP is to engage in scientific discovery that significantly advances knowledge for the prevention and regulation of autoimmune disease. The specific goals enunciated in pursuit of this mission are:
The current Study Group includes the following cooperative agreements and principal investigators (links are to non-federal websites):
Drs. Eisenbarth, Fathman, Hafler, Nepom, Greiner, Sherman, and von Herrath sit on the Group’s Steering Committee, with Dr. von Herrath serving as Chair. NIH representatives to the Steering Committee include Beena Akolkar (NIDDK) and Thomas Esch (NIAID).
The Steering Committee of the CSGADP has access to a discretionary fund to support additional projects that the Committee finds to be in keeping with the group’s mission. Projects eligible for discretionary fund support may include:
back to top
Last Updated August 08, 2011